Study identifier:D0980C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2008-002153-20
CTIS identifier:N/A
A Phase 1, Single-Centre, Randomised, Double-Blind (within panels), Placebo-Controlled Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1704 After Administration of Oral Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers
Healthy Volunteers
Phase 1
Yes
AZD1704, Placebo
All
16
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Four different oral dose levels of a suspension containing AZD1704 | Drug: AZD1704 single dose oral suspension, 4 different dose levels |
Placebo Comparator: 2 oral suspension | Drug: Placebo single dose oral suspension |